within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA19_Fenoldopam;

model Fenoldopam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.833333333333333e-05,
    adminDuration = 600,
    adminMass = 0.3 / 1000000,
    adminCount = 1,
    Vd = 0.00045,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00028000000000000003,
    k12 = 4.083333333333334e-05,
    k21 = 4.083333333333334e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fenoldopam</td></tr><tr><td>ATC code:</td><td>C01CA19</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.3</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.45</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.0</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fenoldopam is a selective dopamine D1-receptor agonist used primarily as a rapid-acting antihypertensive agent. It is used in the management of severe hypertension, including hypertensive emergencies, by causing vasodilation. Fenoldopam is administered intravenously and is approved for use in clinical settings such as hospitals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous infusion.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01CA19 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fenoldopam;
